These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 21421070

  • 1. A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells.
    Inamoto Y, Flowers ME, Appelbaum FR, Carpenter PA, Deeg HJ, Furlong T, Kiem HP, Mielcarek M, Nash RA, Storb RF, Witherspoon RP, Storer BE, Martin PJ.
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1088-92. PubMed ID: 21421070
    [Abstract] [Full Text] [Related]

  • 2. Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis.
    Snyder DS, Palmer J, Gaal K, Stein AS, Pullarkat V, Sahebi F, Vora N, Nakamura R, Forman SJ.
    Biol Blood Marrow Transplant; 2010 Feb; 16(2):281-6. PubMed ID: 19786111
    [Abstract] [Full Text] [Related]

  • 3. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
    Rosenbeck LL, Kiel PJ, Kalsekar I, Vargo C, Baute J, Sullivan CK, Wood L, Abdelqader S, Schwartz J, Srivastava S, Abonour R, Robertson MJ, Nelson RP, Cornetta K, Fausel CA, Farag SS.
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
    [Abstract] [Full Text] [Related]

  • 4. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.
    Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, van der Jagt R, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR.
    Blood; 1998 Oct 01; 92(7):2303-14. PubMed ID: 9746768
    [Abstract] [Full Text] [Related]

  • 5. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
    Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, Gallagher G, Kerr H, Kuruvilla J, Lee SJ, Moore J, Nevill T, Popradi G, Roy J, Schultz KR, Szwajcer D, Toze C, Foley R, Cell Therapy Transplant Canada.
    Lancet Haematol; 2020 Feb 01; 7(2):e100-e111. PubMed ID: 31958417
    [Abstract] [Full Text] [Related]

  • 6. High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention.
    Holtzman NG, Curtis LM, Salit RB, Shaffer BC, Pirsl F, Ostojic A, Steinberg SM, Schulz E, Wilder JS, Hughes TE, Rose J, Memon S, Korngold R, Gea-Banacloche JC, Fowler DH, Hakim FT, Gress RE, Bishop MR, Pavletic SZ.
    Blood Adv; 2024 Aug 27; 8(16):4294-4310. PubMed ID: 38669315
    [Abstract] [Full Text] [Related]

  • 7. Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease.
    Vasu S, Geyer S, Bingman A, Auletta JJ, Jaglowski S, Elder P, O'Donnell LC, Bradbury H, Kitzler R, Andritsos L, Blum W, Klisovic R, Penza S, Efebera Y, Hofmeister C, Benson DM, Muthusamy N, Lozanski G, Devine SM.
    Biol Blood Marrow Transplant; 2016 Apr 27; 22(4):658-668. PubMed ID: 26743340
    [Abstract] [Full Text] [Related]

  • 8. Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study.
    Carnevale-Schianca F, Leisenring W, Martin PJ, Furlong T, Schoch G, Anasetti C, Appelbaum FR, Carpenter PA, Deeg HJ, Kiem HP, Storb R, McDonald GB, Nash RA.
    Biol Blood Marrow Transplant; 2009 Jun 27; 15(6):749-56. PubMed ID: 19450760
    [Abstract] [Full Text] [Related]

  • 9. Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia.
    Inamoto Y, Flowers ME, Wang T, Urbano-Ispizua A, Hemmer MT, Cutler CS, Couriel DR, Alousi AM, Antin JH, Gale RP, Gupta V, Hamilton BK, Kharfan-Dabaja MA, Marks DI, Ringdén OT, Socié G, Solh MM, Akpek G, Cairo MS, Chao NJ, Hayashi RJ, Nishihori T, Reshef R, Saad A, Shah A, Teshima T, Tallman MS, Wirk B, Spellman SR, Arora M, Martin PJ.
    Biol Blood Marrow Transplant; 2015 Oct 27; 21(10):1776-82. PubMed ID: 26033280
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
    Ho VT, Aldridge J, Kim HT, Cutler C, Koreth J, Armand P, Antin JH, Soiffer RJ, Alyea EP.
    Biol Blood Marrow Transplant; 2009 Jul 27; 15(7):844-50. PubMed ID: 19539216
    [Abstract] [Full Text] [Related]

  • 12. Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
    Alyea EP, Li S, Kim HT, Cutler C, Ho V, Soiffer RJ, Antin JH.
    Biol Blood Marrow Transplant; 2008 Aug 27; 14(8):920-6. PubMed ID: 18640576
    [Abstract] [Full Text] [Related]

  • 13. Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.
    Luznik L, Pasquini MC, Logan B, Soiffer RJ, Wu J, Devine SM, Geller N, Giralt S, Heslop HE, Horowitz MM, Jones RJ, Litzow MR, Mendizabal A, Muffly L, Nemecek ER, O'Donnell L, O'Reilly RJ, Palencia R, Schetelig J, Shune L, Solomon SR, Vasu S, Ho VT, Perales MA.
    J Clin Oncol; 2022 Feb 01; 40(4):356-368. PubMed ID: 34855460
    [Abstract] [Full Text] [Related]

  • 14. Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation.
    Ram R, Storer B, Mielcarek M, Sandmaier BM, Maloney DG, Martin PJ, Flowers ME, Chua BK, Rotta M, Storb R.
    Biol Blood Marrow Transplant; 2012 Mar 01; 18(3):414-22. PubMed ID: 21875504
    [Abstract] [Full Text] [Related]

  • 15. Comparison of Tacrolimus and Cyclosporine Combined With Methotrexate for Graft Versus Host Disease Prophylaxis After Allogeneic Hematopoietic Cell Transplantation.
    Huang B, Lin X, Zhang Z, Zhang Y, Zheng Z, Zhong C, He X, Chen M.
    Transplantation; 2020 Feb 01; 104(2):428-436. PubMed ID: 31283681
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
    Pérez-Simón JA, Martino R, Caballero D, Valcarcel D, Rebollo N, de la Cámara R, de Oteiza JP, Heras I, Calvo MV, Sierra J, San Miguel JF, Grupo Español de Trasplante Hematopoyético (GETH).
    Biol Blood Marrow Transplant; 2008 Jun 01; 14(6):664-71. PubMed ID: 18489992
    [Abstract] [Full Text] [Related]

  • 18. [Study on graft-versus-host disease in the allogeneic peripheral blood stem cell transplantation for the treatment of leukemia].
    Zhang WP, Wang JM, Ju XP, Song XM, Tong SP, Li HM.
    Zhonghua Xue Ye Xue Za Zhi; 2003 Mar 01; 24(3):129-33. PubMed ID: 12697123
    [Abstract] [Full Text] [Related]

  • 19. A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation.
    Törlén J, Ringdén O, Garming-Legert K, Ljungman P, Winiarski J, Remes K, Itälä-Remes M, Remberger M, Mattsson J.
    Haematologica; 2016 Nov 01; 101(11):1417-1425. PubMed ID: 27662016
    [Abstract] [Full Text] [Related]

  • 20. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors.
    Kohrt HE, Turnbull BB, Heydari K, Shizuru JA, Laport GG, Miklos DB, Johnston LJ, Arai S, Weng WK, Hoppe RT, Lavori PW, Blume KG, Negrin RS, Strober S, Lowsky R.
    Blood; 2009 Jul 30; 114(5):1099-109. PubMed ID: 19423725
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.